Lepu Medical
Lepu Medical Technology (Beijing) Co., Ltd., established in 1999, is a prominent Chinese company that develops, manufactures, and markets advanced medical devices and equipment. The company specializes in various areas, including cardiovascular interventions, structural heart diseases, cardiac rhythm management, anesthesia and critical care, in vitro diagnostics, and general surgery. Its product offerings include coronary stents, dilatation balloon catheters, interventional accessories, occlusion devices, mechanical heart valves, electrophysiology catheters, pacemakers, in vitro diagnostic equipment, biomarkers, DSA systems, and surgical staplers. Lepu Medical has established itself as a global leader in these fields, demonstrating a commitment to innovation and quality in healthcare solutions.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
Lepu Biotechnology Co., Ltd. is a China-based biotech company specializing in tumor immunotherapy. Founded in 2018, it has developed an industrial platform that facilitates the discovery, development, and manufacturing of innovative drug candidates. The company's core offerings include programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) antibodies, an oncolytic virus, and various antibody-drug conjugates (ADCs). These products have advanced into clinical stages I to III, highlighting the company's commitment to advancing cancer treatment through its proprietary technologies.
24tidy is a service platform that specializes in providing laundry and cleaning services, primarily operating in China and Thailand. The company utilizes advanced internet technology to offer users a convenient way to schedule the pickup and drop-off of laundry and dry cleaning items. It operates in over ten cities, ensuring fast and high-quality cleaning for various items, including clothes, shoes, bags, leather goods, and home furnishings like sofa cushions and carpets. In addition to its core laundry services, 24tidy also offers complementary family services such as weekly flower delivery and potted plant rental, enhancing the overall convenience for its users.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.